Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine are told the same thing after their lab results come back. Your TSH is normal, your thyroid is under control, and whatever symptoms you are still experiencing must be coming from somewhere else. And for some patients that is true. But for a significant portion of people on T4 therapy, the problem was never the thyroid itself. It was what happens to the hormone after it leaves the thyroid, and that process almost never gets tested.

To understand why, you need the full picture of how thyroid hormone actually works in the body.

Your thyroid gland produces two main hormones: T4 and T3. T4 is sometimes called the storage hormone because in that form it does not do very much on its own. T3 is the active form, the one that enters your cells and drives the metabolic machinery behind energy production, temperature regulation, and cognitive function. The problem is that your thyroid only produces about 20 percent of your circulating T3 directly. The other 80 percent has to be manufactured elsewhere in the body through a conversion process.

That conversion happens primarily in your liver, kidneys, and gut through a family of enzymes called deiodinases, which are proteins that strip an iodine atom off T4 to create the active T3 form. Deiodinases are what biochemists call selenoproteins, meaning they require the mineral selenium to function. Without adequate selenium, this machinery slows down and T4 accumulates while T3 output drops.

So when a doctor prescribes levothyroxine, which is synthetic T4, the clinical assumption embedded in that prescription is that your body will handle the conversion on its own. Give the system the raw material and let it do the rest. The TSH test, which measures a signaling hormone released by the pituitary gland to tell the thyroid to produce more or less hormone, comes back in range, and from a lab standpoint the case is closed.

But TSH only reflects what the pituitary sees. It does not tell you whether the deiodinase pathway is actually producing usable T3 from that T4, and that gap is where the problem lives for a meaningful number of patients.

A large survey of hypothyroid patients found that 40 percent remained symptomatic even when their labs were normal, reporting fatigue, cognitive difficulty, and persistent weight issues despite TSH values in the reference range. Research on levothyroxine-treated patients with normal TSH found their T3 to T4 ratios were 15 to 20 percent lower than untreated healthy individuals, which points directly to reduced conversion efficiency rather than a problem with dosing.

There are several reasons conversion can be impaired, and they stack on top of each other in ways that make the problem hard to pin down from a single blood test.

Chronic inflammation is one of the strongest suppressors of deiodinase activity. When inflammatory signals are elevated, the body downregulates conversion as part of a broader stress response, which may be adaptive in the short term but becomes a problem when the inflammation is persistent. This is particularly relevant in Hashimoto's thyroiditis, the autoimmune condition that accounts for most cases of hypothyroidism in developed countries. In Hashimoto's, the immune attack on the thyroid simultaneously reduces the 20 percent of T3 the gland produces directly and impairs the peripheral conversion enzymes responsible for the other 80 percent, so the deficit comes from both ends at once.

Liver dysfunction matters here too because the liver handles a substantial portion of the conversion load, and gut dysbiosis can reduce the contribution of intestinal deiodinases, which are more significant than most clinicians account for.

Then there is the genetic layer.

A gene called DIO2 encodes one of the primary conversion enzymes, and a common variant of that gene, present in somewhere between 12 and 36 percent of the population depending on the population studied, reduces the efficiency of that conversion pathway. People who carry this variant have a structural reason why T4 monotherapy will not normalize their tissue T3 levels no matter how well their TSH looks on paper. A study in the Journal of Clinical Endocrinology and Metabolism found that patients with this DIO2 variant reported lower psychological well-being on T4-only treatment and showed measurably better outcomes when T3 was added to their regimen. Their TSH was telling the doctor one thing while their cells were experiencing something else entirely.

The practical question is what to do with this.

The first step is simply to measure free T3 alongside TSH, because free T3 tells you whether the conversion process is producing active hormone at the tissue level rather than just telling you what the pituitary thinks is happening. If free T3 is low or in the lower portion of the reference range while TSH looks normal, that pattern is the signature of a conversion problem and not a dosing problem, and treating it by adjusting levothyroxine will make the TSH look better without solving the underlying issue.

On the nutrient side, since deiodinases are selenoproteins, selenium status directly sets the ceiling on how well that conversion can function. Research on selenium-deficient patients shows elevated free T4 to T3 ratios, exactly the pattern you would expect if the conversion enzyme is not working at full capacity, and supplementation at around 200 micrograms per day has shown support for deiodinase activity. This is worth discussing with your provider before adding anything, particularly because selenium has a relatively narrow window between therapeutic and excessive intake.

For patients with a confirmed DIO2 variant or persistently low free T3 despite adequate T4 dosing, combination therapy with both T4 and T3, or a desiccated thyroid preparation that contains both naturally, is worth an informed conversation with an endocrinologist.

The deeper issue here is what TSH was designed to measure and what it was never designed to do. TSH is a pituitary output signal, and the pituitary has its own local conversion machinery that may not reflect what is happening in the brain, the heart, the muscle, or the gut. Normalizing TSH tells you the pituitary is satisfied. It says nothing about whether your cells are.

Levothyroxine is not a failed medication. For many people it works exactly as intended. But the standard of care that pairs it with TSH monitoring alone treats the gland as if the gland were the whole system, when the gland is only responsible for 20 percent of what your body actually runs on.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness